AR118805A2 - Terapia de combinación para el tratamiento de la diabetes - Google Patents
Terapia de combinación para el tratamiento de la diabetesInfo
- Publication number
- AR118805A2 AR118805A2 ARP200101201A ARP200101201A AR118805A2 AR 118805 A2 AR118805 A2 AR 118805A2 AR P200101201 A ARP200101201 A AR P200101201A AR P200101201 A ARP200101201 A AR P200101201A AR 118805 A2 AR118805 A2 AR 118805A2
- Authority
- AR
- Argentina
- Prior art keywords
- group
- mono
- alkyl
- formula
- weight
- Prior art date
Links
- 238000002648 combination therapy Methods 0.000 title 1
- 206010012601 diabetes mellitus Diseases 0.000 title 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 3
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 3
- 125000005843 halogen group Chemical group 0.000 abstract 3
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 2
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 229920002785 Croscarmellose sodium Polymers 0.000 abstract 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 abstract 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 abstract 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 abstract 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 abstract 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 abstract 1
- 229920002472 Starch Polymers 0.000 abstract 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 abstract 1
- 125000003282 alkyl amino group Chemical group 0.000 abstract 1
- 125000005115 alkyl carbamoyl group Chemical group 0.000 abstract 1
- 239000011230 binding agent Substances 0.000 abstract 1
- 239000001506 calcium phosphate Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 229960001681 croscarmellose sodium Drugs 0.000 abstract 1
- 229960000913 crospovidone Drugs 0.000 abstract 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 abstract 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 abstract 1
- 229940038472 dicalcium phosphate Drugs 0.000 abstract 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 abstract 1
- 239000003085 diluting agent Substances 0.000 abstract 1
- 239000007884 disintegrant Substances 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 abstract 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 abstract 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 abstract 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 abstract 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 abstract 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 abstract 1
- 239000008101 lactose Substances 0.000 abstract 1
- 229960001375 lactose Drugs 0.000 abstract 1
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 abstract 1
- 229960003105 metformin Drugs 0.000 abstract 1
- 229920000609 methyl cellulose Polymers 0.000 abstract 1
- 239000001923 methylcellulose Substances 0.000 abstract 1
- 235000010981 methylcellulose Nutrition 0.000 abstract 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 abstract 1
- 239000008108 microcrystalline cellulose Substances 0.000 abstract 1
- 229940016286 microcrystalline cellulose Drugs 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 abstract 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 abstract 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 abstract 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 abstract 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 abstract 1
- 239000008109 sodium starch glycolate Substances 0.000 abstract 1
- 229940079832 sodium starch glycolate Drugs 0.000 abstract 1
- 229920003109 sodium starch glycolate Polymers 0.000 abstract 1
- 229940032147 starch Drugs 0.000 abstract 1
- 235000019698 starch Nutrition 0.000 abstract 1
- 239000008107 starch Substances 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Inorganic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Emergency Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Child & Adolescent Psychology (AREA)
- Vascular Medicine (AREA)
- Dermatology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Reivindicación 1: Una composición farmacéutica caracterizada porque comprende (a) metformina o una sal farmacéuticamente aceptable de la misma en una cantidad en el rango de 100 mg a 2000 mg; y (b) un compuesto de fórmula (1) donde el anillo A es un resto de fórmula (2) en donde R¹ᵃ es un átomo de halógeno, un grupo alquilo C₁₋₄, o un grupo alcoxi C₁₋₄, y R²ᵃ y R³ᵃ son átomos de hidrógeno; y el anillo B es un resto de fórmula (3) en donde R⁴ᵃ es un grupo fenilo opcionalmente sustituido con un sustituyente seleccionado del grupo que consiste de un átomo de halógeno, un grupo ciano, un grupo alquilo C₁₋₄, un grupo halo-alquilo C₁₋₄, un grupo alcoxi C₁₋₄, un grupo halo-alcoxi C₁₋₄, un grupo mono- o di-alquil C₁₋₄amino, un grupo carbamoilo, y un grupo mono- o di-alquil C₁₋₄carbamoilo; o un grupo heterociclilo opcionalmente sustituido con un átomo de halógeno, un grupo ciano, un grupo alquilo C₁₋₄, un grupo alcoxi C₁₋₄, un grupo carbamoilo, o un grupo mono- o di-alquil C₁₋₄carbamoilo, y R⁵ᵃ es un átomo de hidrógeno; e Y es -CH₂-; o una sal farmacéuticamente aceptable del mismo; en una cantidad de desde 10 mg a 300 mg; y entre 5% y 50% en peso de diluyente seleccionado del grupo que consiste de lactosa, celulosa microcristalina, fosfato de dicalcio, y almidón; entre 1% y 10% en peso de aglutinante seleccionado del grupo que consiste de polivinilpirrolidona, metilcelulosa, hidroxipropil celulosa, e hidroxipropil metilcelulosa; y entre 1% y 10% en peso de desintegrante seleccionado del grupo que consiste de glicolato sódico de almidón, croscarmelosa de sodio, y crospovidona.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US22388109P | 2009-07-08 | 2009-07-08 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR118805A2 true AR118805A2 (es) | 2021-11-03 |
Family
ID=43427948
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP100102481A AR077464A1 (es) | 2009-07-08 | 2010-07-08 | Terapia de combinacion para el tratamiento de la diabetes |
ARP200101201A AR118805A2 (es) | 2009-07-08 | 2020-04-29 | Terapia de combinación para el tratamiento de la diabetes |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP100102481A AR077464A1 (es) | 2009-07-08 | 2010-07-08 | Terapia de combinacion para el tratamiento de la diabetes |
Country Status (39)
Country | Link |
---|---|
US (4) | US20110009347A1 (es) |
EP (1) | EP2451482B1 (es) |
JP (3) | JP6115986B2 (es) |
KR (1) | KR101799944B1 (es) |
CN (2) | CN106983744A (es) |
AR (2) | AR077464A1 (es) |
AU (2) | AU2010270669A1 (es) |
BR (1) | BR112012000502B1 (es) |
CA (1) | CA2767811C (es) |
CL (1) | CL2012000024A1 (es) |
CO (1) | CO6430453A2 (es) |
CR (1) | CR20120062A (es) |
CY (1) | CY1121853T1 (es) |
DK (1) | DK2451482T3 (es) |
EA (1) | EA020009B1 (es) |
EC (1) | ECSP12011582A (es) |
ES (1) | ES2732703T3 (es) |
HN (1) | HN2012000031A (es) |
HR (1) | HRP20191148T1 (es) |
HU (1) | HUE045367T2 (es) |
IL (2) | IL259475B1 (es) |
IN (1) | IN2012DN00639A (es) |
LT (1) | LT2451482T (es) |
ME (1) | ME03508B (es) |
MX (1) | MX2012000488A (es) |
MY (1) | MY174002A (es) |
NI (1) | NI201200005A (es) |
PE (1) | PE20121046A1 (es) |
PL (1) | PL2451482T3 (es) |
PT (1) | PT2451482T (es) |
RS (1) | RS58871B1 (es) |
SG (2) | SG10201403900PA (es) |
SI (1) | SI2451482T1 (es) |
TR (1) | TR201909599T4 (es) |
TW (1) | TWI532481B (es) |
UA (1) | UA107578C2 (es) |
UY (1) | UY32778A (es) |
WO (1) | WO2011005811A1 (es) |
ZA (1) | ZA201200918B (es) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2066597A4 (en) | 2006-09-21 | 2011-07-27 | Mcgowan Kenneth A | METHODS OF USING REFRACTORY LININGS AND / OR CHEMICAL BARRIERS OF CALCIUM HEXA ALUMINATE IN ALKALI OR HIGHLY ALKALI ENVIRONMENTS |
PL2200606T3 (pl) * | 2007-09-10 | 2018-08-31 | Janssen Pharmaceutica, N.V. | Sposób wytwarzania związków użytecznych jako inhibitory SGLT2 |
US9056850B2 (en) * | 2008-10-17 | 2015-06-16 | Janssen Pharmaceutica N.V. | Process for the preparation of compounds useful as inhibitors of SGLT |
US20110009347A1 (en) | 2009-07-08 | 2011-01-13 | Yin Liang | Combination therapy for the treatment of diabetes |
ES2416459T3 (es) | 2009-07-10 | 2013-08-01 | Janssen Pharmaceutica, N.V. | Procedimiento de cristalización para 1-( -D-glucopiranosil)-4-metil-3-[5-(4-fluorofenil)-2-tienilmetil]benceno |
SG10201500258WA (en) * | 2009-10-14 | 2015-03-30 | Janssen Pharmaceutica Nv | Process for the preparation of compounds useful as inhibitors of sglt2 |
SI2568988T1 (sl) | 2010-05-11 | 2016-10-28 | Janssen Pharmaceutica N.V. | Farmacevtske formulacije, obsegajoče 1-(beta-D-glukopiranozil)-2-tienilmetilbenzenske derivate kot inhibitorje SGLT |
CA2797095A1 (en) | 2010-05-13 | 2011-11-17 | Indiana University Research And Technology Corporation | Glucagon superfamily peptides exhibiting nuclear hormone receptor activity |
CA2804506C (en) * | 2010-07-06 | 2018-08-21 | Janssen Pharmaceutica Nv | Formulation for co-therapy treatment of diabetes |
WO2012140120A1 (en) | 2011-04-13 | 2012-10-18 | Janssen Pharmaceutica Nv | Process for the preparation of compounds useful as inhibitors of sglt2 |
US9035044B2 (en) | 2011-05-09 | 2015-05-19 | Janssen Pharmaceutica Nv | L-proline and citric acid co-crystals of (2S, 3R, 4R, 5S,6R)-2-(3-((5-(4-fluorophenyl)thiopen-2-yl)methyl)4-methylphenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol |
BR112014005909B1 (pt) * | 2011-09-15 | 2021-05-18 | Friulchem Spa | composições para administração oral a animais, métodos de produção das mesmas e usos das mesmas |
RU2014117678A (ru) | 2011-11-17 | 2015-12-27 | Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн | Пептиды глюкагонового суперсемейства, обладающие глюкокортикоидной рецепторной активностью |
CN102743540A (zh) * | 2012-06-14 | 2012-10-24 | 黄培光 | 联合降糖方 |
CN103641822B (zh) * | 2013-10-21 | 2016-06-08 | 江苏奥赛康药业股份有限公司 | 一种卡格列净化合物及其药物组合物 |
EP3238744A4 (en) | 2014-12-25 | 2018-09-26 | International Institute of Cancer Immunology, Inc. | Method for modifying t cell population |
US20170071970A1 (en) | 2015-09-15 | 2017-03-16 | Janssen Pharmaceutica Nv | Co-therapy comprising canagliflozin and phentermine for the treatment of obesity and obesity related disorders |
TWI795462B (zh) * | 2017-11-17 | 2023-03-11 | 日商鹽野義製藥股份有限公司 | 光安定性及溶出性優異的醫藥製劑 |
JP6591010B2 (ja) | 2017-11-30 | 2019-10-16 | キヤノン株式会社 | 電源装置及び画像形成装置 |
Family Cites Families (171)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2799241A (en) * | 1949-01-21 | 1957-07-16 | Wisconsin Alumni Res Found | Means for applying coatings to tablets or the like |
US4160861A (en) * | 1977-10-03 | 1979-07-10 | Merck & Co., Inc. | Method for the separation of antibiotic macrolides |
US4584369A (en) * | 1981-07-31 | 1986-04-22 | Sloan-Kettering Institute For Cancer Research | Anti-leukemic beta-glycosyl C-nucleosides |
JPS5939889A (ja) | 1982-08-30 | 1984-03-05 | Noguchi Kenkyusho | 2,4,6↓−トリ↓−0↓−アセチル↓−3↓−デオキシ↓−ヘキソノ↓−1,5↓−ラクトンの製造方法 |
JP2544609B2 (ja) | 1986-10-07 | 1996-10-16 | 和光純薬工業株式会社 | Tcnq錯体 |
US4863957A (en) | 1987-12-21 | 1989-09-05 | Rorer Pharmaceutical Corporation | Novel HMG-CoA reductase inhibitors |
CA1327013C (en) | 1988-06-23 | 1994-02-15 | Peter Rex Brawn | Cosmetic composition |
JP2786896B2 (ja) | 1988-08-19 | 1998-08-13 | ワーナー―ランバート・コンパニー | 置換されたジヒドロイソキノリノンおよび関連化合物 |
ES2075403T3 (es) * | 1990-08-24 | 1995-10-01 | Spirig Ag Pharmazeutische Prap | Procedimiento para la fabricacion de pellets. |
JPH04253974A (ja) | 1991-02-05 | 1992-09-09 | Ishihara Sangyo Kaisha Ltd | スルホニル尿素系化合物、それらの製造方法及びそれらを含有する除草剤 |
EP0517969A1 (en) * | 1991-06-10 | 1992-12-16 | AUSIMONT S.p.A. | Process for increasing the bleaching efficiency of an inorganic persalt or of hydrogen peroxide |
US5149838A (en) * | 1991-09-20 | 1992-09-22 | Merck & Co., Inc. | Intermediates for substituted azetidinones useful as anti-inflammatory and antidegenerative agents |
US5610294A (en) * | 1991-10-11 | 1997-03-11 | The Du Pont Merck Pharmaceutical Company | Substituted cyclic carbonyls and derivatives thereof useful as retroviral protease inhibitors |
CN1071924A (zh) | 1991-10-29 | 1993-05-12 | 纳幕尔杜邦公司 | 除草的三唑羧酸酰胺 |
GB9208161D0 (en) | 1992-04-14 | 1992-05-27 | Pfizer Ltd | Indoles |
US5334225A (en) | 1992-07-15 | 1994-08-02 | Kao Corporation | Keratinous fiber dye composition containing a 2-substituted amino-5-alkylphenol derivative coupler |
US5731292A (en) * | 1992-11-12 | 1998-03-24 | Tanabe Seiyaku Co., Ltd. | Dihydrochalcone derivatives which are hypoglycemic agents |
CA2102591C (en) * | 1992-11-12 | 2000-12-26 | Kenji Tsujihara | Hypoglycemic agent |
DE4243279A1 (de) | 1992-12-21 | 1994-06-23 | Bayer Ag | Substituierte Triole |
US6297363B1 (en) * | 1993-02-12 | 2001-10-02 | Nomura Co., Ltd. | Glycoside indoles |
JPH06256354A (ja) | 1993-03-01 | 1994-09-13 | Nippon Nohyaku Co Ltd | 新規テトラゾール化合物及びその製法 |
JP3187611B2 (ja) | 1993-05-17 | 2001-07-11 | キヤノン株式会社 | 液晶性化合物、これを含む液晶組成物、それを有する液晶素子、それらを用いた表示方法および表示装置 |
JPH07242526A (ja) | 1994-03-03 | 1995-09-19 | Sogo Yatsukou Kk | 化粧料 |
US5830873A (en) * | 1994-05-11 | 1998-11-03 | Tanabe Seiyaku Co., Ltd. | Propiophenone derivative and a process for preparing the same |
EP0732921A4 (en) | 1994-09-30 | 1998-09-02 | Ohio State Res Found | C-GLYCOSIDANOLOGIST OF N- (4-HYDROXYPHENYL) RETINAMIDE-O-GLUCURONIDE |
US5780483A (en) * | 1995-02-17 | 1998-07-14 | Smithkline Beecham Corporation | IL-8 receptor antagonists |
PL322529A1 (en) | 1995-04-07 | 1998-02-02 | Ciba Geigy Ag | Complex compositions containing benazeoprile or benazeprilate and valsartan |
ES2233982T3 (es) | 1995-10-31 | 2005-06-16 | Eli Lilly And Company | Diaminas antitromboticas. |
JP3059088B2 (ja) * | 1995-11-07 | 2000-07-04 | 田辺製薬株式会社 | プロピオフェノン誘導体およびその製法 |
US5723495A (en) | 1995-11-16 | 1998-03-03 | The University Of North Carolina At Chapel Hill | Benzamidoxime prodrugs as antipneumocystic agents |
JPH09263549A (ja) | 1996-01-25 | 1997-10-07 | Fujisawa Pharmaceut Co Ltd | ベンゼン誘導体の製造法 |
IL121525A0 (en) * | 1996-08-26 | 1998-02-08 | Tanabe Seiyaku Co | Process for preparing optically active benzothiazepine compound and intermediate therefor |
PT850948E (pt) * | 1996-12-26 | 2002-08-30 | Tanabe Seiyaku Co | Derivados propiofenona e processo para a preparacao dos mesmos |
US6153632A (en) * | 1997-02-24 | 2000-11-28 | Rieveley; Robert B. | Method and composition for the treatment of diabetes |
AU6422298A (en) | 1997-03-25 | 1998-10-20 | Takeda Chemical Industries Ltd. | Pharmaceutical composition containing a phosphorylamide and an ayntibiotic |
JP4523153B2 (ja) * | 1998-03-19 | 2010-08-11 | ブリストル−マイヤーズ スクイブ カンパニー | 易溶性薬物の二層性放出制御送達システムおよび方法 |
PE20000559A1 (es) | 1998-05-27 | 2000-07-05 | Merck & Co Inc | Formulacion de tabletas comprimidas de efavirenz |
WO1999065861A1 (de) | 1998-06-18 | 1999-12-23 | Merck Patent Gmbh | Verfahren zur symmetrischen und unsymmetrischen disubstitution von carbonsäureamiden mit organotitanaten und grignard-reagenzien |
FR2780403B3 (fr) * | 1998-06-24 | 2000-07-21 | Sanofi Sa | Nouvelle forme de l'irbesartan, procedes pour obtenir ladite forme et compositions pharmaceutiques en contenant |
ATE250418T1 (de) | 1998-07-15 | 2003-10-15 | Merck Sante Sas | Tabletten enthaltend eine kombination von glibenclamid und metformin |
JP2000034239A (ja) | 1998-07-16 | 2000-02-02 | Asahi Glass Co Ltd | トリフルオロメチル化芳香族化合物の製造方法 |
JP3857429B2 (ja) | 1998-07-17 | 2006-12-13 | ポーラ化成工業株式会社 | 含硫黄抗真菌剤 |
US6069238A (en) * | 1998-09-30 | 2000-05-30 | Eli Lilly And Company | Spirocyclic C-glycosides |
DE69926148D1 (en) | 1998-11-09 | 2005-08-18 | Black James Foundation | Gastrin und cholecystokinin rezeptor ligande |
CN1230162C (zh) | 1998-11-12 | 2005-12-07 | 史密丝克莱恩比彻姆有限公司 | 改进释放胰岛素致敏剂和另一抗糖尿病药的药用组合物 |
US20020032164A1 (en) * | 1998-12-30 | 2002-03-14 | Dale Roderic M. K. | Antimicrobial compounds and methods for their use |
GB9912961D0 (en) | 1999-06-03 | 1999-08-04 | Pfizer Ltd | Metalloprotease inhibitors |
PH12000002657B1 (en) * | 1999-10-12 | 2006-02-21 | Bristol Myers Squibb Co | C-aryl glucoside SGLT2 inhibitors |
US6515117B2 (en) * | 1999-10-12 | 2003-02-04 | Bristol-Myers Squibb Company | C-aryl glucoside SGLT2 inhibitors and method |
US6586438B2 (en) | 1999-11-03 | 2003-07-01 | Bristol-Myers Squibb Co. | Antidiabetic formulation and method |
CA2389928C (en) | 1999-11-03 | 2010-03-23 | Bristol-Myers Squibb Company | Method for treating diabetes |
JP3450810B2 (ja) * | 2000-01-31 | 2003-09-29 | キヤノン株式会社 | 脂肪族ポリエステル、脂肪族ポリエステルの製造方法およびセルロースの再資源化方法 |
JP4456768B2 (ja) | 2000-02-02 | 2010-04-28 | 壽製薬株式会社 | C−配糖体を含有する薬剤 |
US6627611B2 (en) * | 2000-02-02 | 2003-09-30 | Kotobuki Pharmaceutical Co Ltd | C-glycosides and preparation of thereof as antidiabetic agents |
JP2003525288A (ja) | 2000-03-03 | 2003-08-26 | ファイザー・プロダクツ・インク | 抗炎症剤/鎮痛剤としてのピラゾールエーテル誘導体 |
MXPA02009034A (es) * | 2000-03-17 | 2003-09-10 | Kissei Pharmaceutical | Derivados de glucopiranosiloxibencilbenceno, composiciones medicinales conteniendo los mismos e intermediarios para la preparacion de los derivados. |
US6555519B2 (en) * | 2000-03-30 | 2003-04-29 | Bristol-Myers Squibb Company | O-glucosylated benzamide SGLT2 inhibitors and method |
US6683056B2 (en) * | 2000-03-30 | 2004-01-27 | Bristol-Myers Squibb Company | O-aryl glucoside SGLT2 inhibitors and method |
GB0011098D0 (en) | 2000-05-08 | 2000-06-28 | Black James Foundation | Pharmaceutical compositions comprising protpn pump inhibitors and gastrin/cholecystokinin receptor ligands |
EP1172362A1 (de) | 2000-07-11 | 2002-01-16 | Basf Aktiengesellschaft | Azadioxacycloalkene und ihre Verwendung zur Bekämpfung von Schadpilzen und tierischen Schädlingen |
KR100426030B1 (ko) * | 2000-07-22 | 2004-04-03 | (주) 한켐 | 락톤계 당화합물에서의 키랄성 전환방법 |
EP1326829A2 (en) | 2000-09-29 | 2003-07-16 | Bayer Pharmaceuticals Corporation | 17-beta-hydroxysteroid dehydrogenase-ii inhibitors |
WO2002036602A1 (fr) | 2000-11-02 | 2002-05-10 | Ajinomoto Co., Inc. | Nouveaux derives du pyrazole et remedes au diabete contenant ces derniers |
JP2002167430A (ja) | 2000-12-01 | 2002-06-11 | Canon Inc | 脂肪族ポリエステル、脂肪族ポリエステルの製造方法およびデンプンの資源化方法 |
US6476352B2 (en) * | 2000-12-18 | 2002-11-05 | General Electric Company | Laser beam stop sensor and method for automatically detecting the presence of laser beam stop material using a laser beam stop sensor |
WO2002053573A1 (fr) * | 2000-12-28 | 2002-07-11 | Kissei Pharmaceutical Co., Ltd. | Derives de glucopyranosiloxypyrazole et leur utilisation dans des medicaments |
CA2438593C (en) | 2001-02-26 | 2010-09-21 | Kissei Pharmaceutical Co., Ltd. | Glucopyranosyloxypyrazole derivatives and medicinal use thereof |
ES2350084T3 (es) | 2001-02-27 | 2011-01-18 | Kissei Pharmaceutical Co., Ltd. | Derivados de glucopiranosiloxipirazol y uso médico de los mismos. |
JP4190290B2 (ja) | 2001-03-02 | 2008-12-03 | ユニバーシティー オブ ウエスタン オンタリオ | 放射能標識された化合物のポリマー前駆体、ならびにその作製および使用法 |
US6936590B2 (en) * | 2001-03-13 | 2005-08-30 | Bristol Myers Squibb Company | C-aryl glucoside SGLT2 inhibitors and method |
US6774112B2 (en) * | 2001-04-11 | 2004-08-10 | Bristol-Myers Squibb Company | Amino acid complexes of C-aryl glucosides for treatment of diabetes and method |
EP1389621A4 (en) * | 2001-04-27 | 2005-05-11 | Ajinomoto Kk | N-SUBSTITUTED PYRAZOLYL-O-GLYCOSIDE DERIVATIVES AND DIABETES CONTAINING THEREOF |
GB0112122D0 (en) | 2001-05-18 | 2001-07-11 | Lilly Co Eli | Heteroaryloxy 3-substituted propanamines |
US7105556B2 (en) | 2001-05-30 | 2006-09-12 | Bristol-Myers Squibb Company | Conformationally constrained analogs useful as antidiabetic and antiobesity agents and method |
CA2455300A1 (en) | 2001-06-20 | 2003-01-03 | Kissei Pharmaceutical Co., Ltd. | Nitrogen-containing heterocyclic derivative, medicinal composition containing the same, medicinal use thereof, and intermediate therefor |
JP4115105B2 (ja) | 2001-07-02 | 2008-07-09 | 協和醗酵工業株式会社 | ピラゾール誘導体 |
WO2003011880A1 (fr) | 2001-07-31 | 2003-02-13 | Kissei Pharmaceutical Co., Ltd. | Derive de glucopyranosyloxybenzylbenzene, composition medicinale contenant ce derive, usage medicinal de cette composition et produit intermediaire pour produire cette composition |
US20030191121A1 (en) * | 2001-08-09 | 2003-10-09 | Miller Ross A. | Piperazine carboxamide intermediates of HIV protease inhibitors and processes for their preparation |
US20030087843A1 (en) * | 2001-09-05 | 2003-05-08 | Washburn William N. | O-pyrazole glucoside SGLT2 inhibitors and method of use |
WO2003035897A2 (en) * | 2001-10-24 | 2003-05-01 | Michael Burton | Enzyme substrates for detecting beta-d-ribofuranosidase activity |
AU2002356903A2 (en) | 2001-11-08 | 2003-05-19 | Sepracor Inc. | Methods for treating depression and other CNS disorders using enantiomerically enriched desmethyl- and didesmethyl-metabolites of citalopram |
AU2002326363B2 (en) | 2001-11-16 | 2008-08-28 | Skinmedica, Inc. | Pharmaceutical and cosmetic compositions containing oxy group-bearing aromatic aldehydes |
JP2003238417A (ja) | 2002-02-18 | 2003-08-27 | Nippon Shoyaku Kenkyusho:Kk | フロレチン配糖体の安定化組成物、該安定化組成物を含有する糖尿病予防・治療剤、および保健食品 |
US6617313B1 (en) * | 2002-03-13 | 2003-09-09 | Council Of Scientific And Industrial Research | Glucopyranoside and process of isolation thereof from pterocarpus marsupium pharmaceutical composition containing the same and use thereof |
US6562791B1 (en) * | 2002-03-29 | 2003-05-13 | Council Of Scientific And Industrial Research | Glucopyranoside, process for isolation thereof, pharmaceutical composition containing same and use thereof |
JP2003313168A (ja) | 2002-04-18 | 2003-11-06 | Kirin Brewery Co Ltd | Bcl−2阻害活性を有する化合物およびその化合物のスクリーニング方法 |
DE60328010D1 (de) | 2002-04-18 | 2009-07-30 | Astrazeneca Ab | Heterocyclische verbindungen |
EP1515701B1 (en) | 2002-06-17 | 2014-09-17 | Inventia Healthcare Private Limited | Process for the manufacture of multilayer tablet compositions comprising thiazolidinedione and biguanide |
DE10231370B4 (de) * | 2002-07-11 | 2006-04-06 | Sanofi-Aventis Deutschland Gmbh | Thiophenglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel |
TWI254635B (en) | 2002-08-05 | 2006-05-11 | Yamanouchi Pharma Co Ltd | Azulene derivative and salt thereof |
CA2478889A1 (en) | 2002-08-09 | 2004-02-19 | Taisho Pharmaceutical Co., Ltd. | Aryl 5-thio-.beta.-d-glucopyranoside derivatives and therapeutic agents for diabetes containing the same |
JP4606876B2 (ja) | 2002-08-27 | 2011-01-05 | キッセイ薬品工業株式会社 | ピラゾール誘導体、それを含有する医薬組成物及びその医薬用途 |
UA80991C2 (en) * | 2002-10-07 | 2007-11-26 | Solid preparation containing an insulin resistance improving drug and an active ingredient useful as a remedy for diabetes | |
US7074826B2 (en) * | 2002-10-07 | 2006-07-11 | Encore Pharmaceuticals, Inc. | R-NSAID esters and their use |
IN192749B (es) | 2002-11-15 | 2004-05-15 | Ranbaxy Lab Ltd | |
DE10258008B4 (de) | 2002-12-12 | 2006-02-02 | Sanofi-Aventis Deutschland Gmbh | Heterocyclische Fluorglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel |
DE10258007B4 (de) * | 2002-12-12 | 2006-02-09 | Sanofi-Aventis Deutschland Gmbh | Aromatische Fluorglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel |
KR20050090437A (ko) * | 2003-01-03 | 2005-09-13 | 브리스톨-마이어스 스큅 컴퍼니 | C-아릴 글루코시드 sglt2 억제제의 제조 방법 |
GB0301259D0 (en) | 2003-01-20 | 2003-02-19 | Novartis Ag | Organic compounds |
EP1597266A4 (en) | 2003-02-27 | 2008-02-20 | Bristol Myers Squibb Co | NON-CRYOGENIC PROCESS FOR THE PRODUCTION OF GLYCOSIDES |
FR2853831A1 (fr) | 2003-03-05 | 2004-10-22 | Usv Ltd | Forme posologique solide a usage oral de metformine et de glyburide et son procede de preparation |
RU2317288C3 (ru) | 2003-03-14 | 2021-03-10 | Астеллас Фарма Инк. | С-гликозидные производные и их соли |
JP2004300102A (ja) * | 2003-03-31 | 2004-10-28 | Kissei Pharmaceut Co Ltd | 縮合複素環誘導体、それを含有する医薬組成物およびその医薬用途 |
AU2003902263A0 (en) | 2003-05-12 | 2003-05-29 | Fujisawa Pharmaceutical Co., Ltd. | Monosaccharide compounds |
CA2529878C (en) | 2003-06-20 | 2012-11-20 | Kissei Pharmaceutical Co., Ltd. | Pyrazole derivative, drug composition containing the same and production intermediate therefor |
JP4979377B2 (ja) | 2003-07-23 | 2012-07-18 | シンタ ファーマシューティカルズ コーポレーション | Cracイオンチャネルを阻害するための薬剤の製造における化合物の使用 |
US8785403B2 (en) | 2003-08-01 | 2014-07-22 | Mitsubishi Tanabe Pharma Corporation | Glucopyranoside compound |
EP1679966A4 (en) * | 2003-08-01 | 2009-05-27 | Janssen Pharmaceutica Nv | BENZIMIDAZOLE-, BENZTRIAZOLE- AND BENZIMIDAZOLONE-SUBSTITUTED O-GLUCOSIDES |
UA86042C2 (en) * | 2003-08-01 | 2009-03-25 | Янссен Фармацевтика Н.В. | Substituted indazole-o-glucosides |
EP1679965A4 (en) * | 2003-08-01 | 2009-05-27 | Janssen Pharmaceutica Nv | SUBSTITUTED FUSED HETEROCYCLIC C-GLYCOSIDES |
EP1651658B2 (en) | 2003-08-01 | 2020-08-12 | Mitsubishi Tanabe Pharma Corporation | Novel compounds having inhibitory activity against sodium-dependant transporter |
EA010422B1 (ru) * | 2003-08-01 | 2008-08-29 | Янссен Фармацевтика Н.В. | Замещённые индол-о-глюкозиды |
EP1680414A4 (en) * | 2003-08-01 | 2009-05-27 | Janssen Pharmaceutica Nv | SUBSTITUTED INDAZOLE-O-GLUCOSIDE |
WO2005058845A2 (en) | 2003-12-19 | 2005-06-30 | Novo Nordisk A/S | Novel glucagon antagonists/inverse agonists |
EP1559419A1 (en) | 2004-01-23 | 2005-08-03 | Fournier Laboratories Ireland Limited | Pharmaceutical formulations comprising metformin and a fibrate, and processes for their obtention |
US7157584B2 (en) * | 2004-02-25 | 2007-01-02 | Takeda Pharmaceutical Company Limited | Benzimidazole derivative and use thereof |
EA011158B1 (ru) * | 2004-03-16 | 2009-02-27 | Бёрингер Ингельхайм Интернациональ Гмбх | Замещённые глюкопиранозилом бензольные производные, содержащие эти соединения лекарственные средства, их применение и способ их получения |
US7803786B2 (en) | 2004-06-17 | 2010-09-28 | Transform Pharmaceuticals, Inc. | Pharmaceutical co-crystal compositions and related methods of use |
US7393836B2 (en) * | 2004-07-06 | 2008-07-01 | Boehringer Ingelheim International Gmbh | D-xylopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture |
JP2008508213A (ja) | 2004-07-27 | 2008-03-21 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | D−グルコピラノシル−フェニル置換環状体、そのような化合物を含有する医薬品、それらの使用及びその製造方法 |
WO2006018150A1 (de) * | 2004-08-11 | 2006-02-23 | Boehringer Ingelheim International Gmbh | D-xylopyranosyl-phenyl-substituierte cyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung |
TW200637839A (en) * | 2005-01-07 | 2006-11-01 | Taisho Pharmaceutical Co Ltd | 1-thio-d-glucitol derivatives |
US20090124702A1 (en) * | 2005-01-25 | 2009-05-14 | Pechetti Siva Satya Krishna Babu | Pharmaceutical Compositions of Metformin |
AR053329A1 (es) | 2005-01-31 | 2007-05-02 | Tanabe Seiyaku Co | Derivados de indol utiles como inhibidores de los transportadores de glucosa dependientes del sodio (sglt) |
WO2006089872A1 (en) * | 2005-02-23 | 2006-08-31 | Boehringer Ingelheim International Gmbh | Glucopyranosyl-substituted ( (hetero)arylethynyl-benzyd-benzene derivatives and use thereof as sodium-dependent glucose cotransporter 2 (sglt2) inhibitors |
ES2338041T3 (es) | 2005-04-15 | 2010-05-03 | Boehringer Ingelheim International Gmbh | Derivados de (heteroariloxi-bencil)-benceno sustituidos con glucopiranosilo en calidad de inhibidores de sglt. |
US7772191B2 (en) * | 2005-05-10 | 2010-08-10 | Boehringer Ingelheim International Gmbh | Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein |
WO2007014894A2 (en) * | 2005-07-27 | 2007-02-08 | Boehringer Ingelheim International Gmbh | Glucopyranosyl-substituted ( (hetero) cycloalyklethynyl-benzyl) -benzene derivatives and use thereof as sodium-dependent glucose cotransporter (sglt) inhibitors |
ATE484499T1 (de) * | 2005-08-30 | 2010-10-15 | Boehringer Ingelheim Int | Glucopyranosyl-substituierte benzyl-derivate, medikamente mit solchen verbindungen, ihre verwendung und herstellungsverfahren dafür |
AR056195A1 (es) | 2005-09-15 | 2007-09-26 | Boehringer Ingelheim Int | Procedimientos para preparar derivados de (etinil-bencil)-benceno sustituidos de glucopiranosilo y compuestos intermedios de los mismos |
CN101057835A (zh) | 2005-09-26 | 2007-10-24 | 刘凤鸣 | 二甲双胍格列本脲的缓释制剂 |
WO2007087441A2 (en) | 2006-01-25 | 2007-08-02 | Synta Pharmaceuticals Corp. | Substituted aromatic compounds for inflammation and immune-related uses |
JP2007230999A (ja) | 2006-01-31 | 2007-09-13 | Kyoto Univ | 置換芳香族ニトリル化合物およびその製造方法 |
TWI370818B (en) | 2006-04-05 | 2012-08-21 | Astellas Pharma Inc | Cocrystal of c-glycoside derivative and l-proline |
US7919598B2 (en) | 2006-06-28 | 2011-04-05 | Bristol-Myers Squibb Company | Crystal structures of SGLT2 inhibitors and processes for preparing same |
TWI418556B (zh) * | 2006-07-27 | 2013-12-11 | Mitsubishi Tanabe Pharma Corp | 吲哚衍生物 |
WO2008020011A1 (en) | 2006-08-15 | 2008-02-21 | Boehringer Ingelheim International Gmbh | Glucopyranosyl-substituted cyclopropylbenzene derivatives, pharmaceutical compositions containing such compounds, their use as sglt inhibitors and process for their manufacture |
US7858587B2 (en) | 2006-09-21 | 2010-12-28 | Boehringer Ingelheim International Gmbh | Glucopyranosyl-substituted difluorobenzyl-benzene derivates, medicaments containing such compounds, their use and process for their manufacture |
KR100812538B1 (ko) | 2006-10-23 | 2008-03-11 | 한올제약주식회사 | 약물 제어방출형 메트포르민-글리메피리드 복합제제 |
JP2010508371A (ja) * | 2006-11-06 | 2010-03-18 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | グルコピラノシル置換フェニル誘導体、該化合物を含有する医薬品及びその使用と製造方法 |
MY157828A (en) * | 2006-11-09 | 2016-07-29 | Boehringer Ingelheim Int | Combination therapy with sglt-2 inhibitors and their pharmaceutical compositions |
UY30730A1 (es) * | 2006-12-04 | 2008-07-03 | Mitsubishi Tanabe Pharma Corp | Forma cristalina del hemihidrato de 1-(b (beta)-d-glucopiranosil) -4-metil-3-[5-(4-fluorofenil) -2-tienilmetil]benceno |
EP2099791B1 (en) | 2006-12-04 | 2012-11-21 | Janssen Pharmaceutica, N.V. | Thienyl-containing glycopyranosyl derivatives as antidiabetics |
EP1956023A1 (en) | 2007-02-06 | 2008-08-13 | Lonza Ag | Method for lithium exchange reactions |
JP2010521492A (ja) | 2007-03-15 | 2010-06-24 | ネクティド,インク. | 徐放性ビグアニド組成物、および即時性ジペプチジルペプチダーゼiv阻害剤組成物を含む抗糖尿病合剤 |
TW200904405A (en) * | 2007-03-22 | 2009-02-01 | Bristol Myers Squibb Co | Pharmaceutical formulations containing an SGLT2 inhibitor |
JP5424571B2 (ja) | 2007-04-12 | 2014-02-26 | 協和発酵キリン株式会社 | トピラマート含有固形製剤 |
WO2008136393A1 (ja) | 2007-04-27 | 2008-11-13 | Ajinomoto Co., Inc. | ラクタム化合物の結晶形およびその製造方法 |
PE20090603A1 (es) | 2007-08-16 | 2009-06-11 | Boehringer Ingelheim Int | Composicion farmaceutica que comprende un inhibidor de sglt2 y un inhibidor de dpp iv |
AR068016A1 (es) | 2007-08-23 | 2009-10-28 | Theracos Inc | Derivados de bencilbenceno, una composicion farmaceutica que los comprende y su uso en el tratamiento de enfermedades mediadas por sglt |
PL2200606T3 (pl) * | 2007-09-10 | 2018-08-31 | Janssen Pharmaceutica, N.V. | Sposób wytwarzania związków użytecznych jako inhibitory SGLT2 |
CL2008003653A1 (es) | 2008-01-17 | 2010-03-05 | Mitsubishi Tanabe Pharma Corp | Uso de un inhibidor de sglt derivado de glucopiranosilo y un inhibidor de dppiv seleccionado para tratar la diabetes; y composicion farmaceutica. |
PE20140960A1 (es) | 2008-04-03 | 2014-08-15 | Boehringer Ingelheim Int | Formulaciones que comprenden un inhibidor de dpp4 |
KR101512386B1 (ko) | 2008-04-08 | 2015-04-17 | 제이더블유중외제약 주식회사 | 미티글리나이드 및 메트포르민 복합제제 및 그의 제조방법 |
CN102105153B (zh) | 2008-05-22 | 2014-03-05 | 百时美施贵宝公司 | Sglt2抑制剂的医药用途和含该抑制剂的组合物 |
WO2010009243A1 (en) | 2008-07-15 | 2010-01-21 | Theracos, Inc. | Deuterated benzylbenzene derivatives and methods of use |
UY32030A (es) | 2008-08-06 | 2010-03-26 | Boehringer Ingelheim Int | "tratamiento para diabetes en pacientes inapropiados para terapia con metformina" |
JP5749168B2 (ja) | 2008-08-22 | 2015-07-15 | セラコス・インコーポレイテッドTheracos, Inc. | Sglt2阻害剤の製造方法 |
US9056850B2 (en) * | 2008-10-17 | 2015-06-16 | Janssen Pharmaceutica N.V. | Process for the preparation of compounds useful as inhibitors of SGLT |
WO2010045656A2 (en) * | 2008-10-17 | 2010-04-22 | Nectid, Inc. | Novel sglt2 inhibitor dosage forms |
EP2389178A4 (en) | 2008-12-01 | 2012-06-06 | Invasc Therapeutic Inc | COMPOSITIONS CONTAINING INHIBITORS OF THE RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM AND LIPOIC ACID COMPOUNDS, AND THEIR USE FOR THE TREATMENT OF RENIN-ANGIOTENSIN-ALDOSTERONE ASSOCIATED DISORDERS |
DK2395983T3 (da) * | 2009-02-13 | 2020-07-13 | Boehringer Ingelheim Int | Farmaceutisk sammensætning omfattende en sglt2-inhibitor, en dpp-iv-inhibitor og eventuelt et yderligere antidiabetisk middel og anvendelser deraf |
EP3338766A1 (en) | 2009-04-24 | 2018-06-27 | Iceutica Pty Ltd. | Production of encapsulated nanoparticles at high volume fractions |
US20100331999A1 (en) | 2009-06-29 | 2010-12-30 | Aronne Louis J | Combination Therapies for the Treatment of Obesity |
US20110009347A1 (en) | 2009-07-08 | 2011-01-13 | Yin Liang | Combination therapy for the treatment of diabetes |
SG10201500258WA (en) | 2009-10-14 | 2015-03-30 | Janssen Pharmaceutica Nv | Process for the preparation of compounds useful as inhibitors of sglt2 |
US8163704B2 (en) | 2009-10-20 | 2012-04-24 | Novartis Ag | Glycoside derivatives and uses thereof |
JP2013523681A (ja) | 2010-03-30 | 2013-06-17 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Sglt2インヒビター及びppar−ガンマアゴニストを含む医薬組成物並びにその使用 |
US20130052266A1 (en) | 2010-05-11 | 2013-02-28 | Mitsubishi Tanabe Pharma Corporation | TABLETS CONTAINING A 1-(beta-D-GLUCOPYRANOSYL)-3-(PHENYLTHIENYLMETHYL)BENZENE COMPOUND |
SI2568988T1 (sl) * | 2010-05-11 | 2016-10-28 | Janssen Pharmaceutica N.V. | Farmacevtske formulacije, obsegajoče 1-(beta-D-glukopiranozil)-2-tienilmetilbenzenske derivate kot inhibitorje SGLT |
CA2804506C (en) | 2010-07-06 | 2018-08-21 | Janssen Pharmaceutica Nv | Formulation for co-therapy treatment of diabetes |
-
2010
- 2010-07-06 US US12/830,479 patent/US20110009347A1/en not_active Abandoned
- 2010-07-07 IL IL259475A patent/IL259475B1/en unknown
- 2010-07-07 DK DK10735109.0T patent/DK2451482T3/da active
- 2010-07-07 JP JP2012519688A patent/JP6115986B2/ja active Active
- 2010-07-07 CA CA2767811A patent/CA2767811C/en active Active
- 2010-07-07 WO PCT/US2010/041136 patent/WO2011005811A1/en active Application Filing
- 2010-07-07 BR BR112012000502-2A patent/BR112012000502B1/pt active IP Right Grant
- 2010-07-07 HU HUE10735109A patent/HUE045367T2/hu unknown
- 2010-07-07 PE PE2012000021A patent/PE20121046A1/es not_active Application Discontinuation
- 2010-07-07 PL PL10735109T patent/PL2451482T3/pl unknown
- 2010-07-07 LT LTEP10735109.0T patent/LT2451482T/lt unknown
- 2010-07-07 MX MX2012000488A patent/MX2012000488A/es active IP Right Grant
- 2010-07-07 SG SG10201403900PA patent/SG10201403900PA/en unknown
- 2010-07-07 PT PT10735109T patent/PT2451482T/pt unknown
- 2010-07-07 CN CN201710167924.4A patent/CN106983744A/zh active Pending
- 2010-07-07 IN IN639DEN2012 patent/IN2012DN00639A/en unknown
- 2010-07-07 ES ES10735109T patent/ES2732703T3/es active Active
- 2010-07-07 AU AU2010270669A patent/AU2010270669A1/en not_active Abandoned
- 2010-07-07 CN CN2010800406265A patent/CN102497881A/zh active Pending
- 2010-07-07 TR TR2019/09599T patent/TR201909599T4/tr unknown
- 2010-07-07 ME MEP-2019-178A patent/ME03508B/me unknown
- 2010-07-07 SI SI201031889T patent/SI2451482T1/sl unknown
- 2010-07-07 EP EP10735109.0A patent/EP2451482B1/en active Active
- 2010-07-07 RS RS20190763A patent/RS58871B1/sr unknown
- 2010-07-07 KR KR1020127002985A patent/KR101799944B1/ko active IP Right Grant
- 2010-07-07 SG SG2011097177A patent/SG177417A1/en unknown
- 2010-07-07 UA UAA201201281A patent/UA107578C2/ru unknown
- 2010-07-07 MY MYPI2012000030A patent/MY174002A/en unknown
- 2010-07-07 EA EA201270144A patent/EA020009B1/ru unknown
- 2010-07-08 UY UY0001032778A patent/UY32778A/es not_active Application Discontinuation
- 2010-07-08 TW TW099122409A patent/TWI532481B/zh active
- 2010-07-08 AR ARP100102481A patent/AR077464A1/es unknown
-
2012
- 2012-01-05 IL IL217395A patent/IL217395A0/en unknown
- 2012-01-05 CL CL2012000024A patent/CL2012000024A1/es unknown
- 2012-01-06 EC EC2012011582A patent/ECSP12011582A/es unknown
- 2012-01-06 CO CO12002313A patent/CO6430453A2/es active IP Right Grant
- 2012-01-06 HN HN2012000031A patent/HN2012000031A/es unknown
- 2012-01-06 NI NI201200005A patent/NI201200005A/es unknown
- 2012-02-07 ZA ZA2012/00918A patent/ZA201200918B/en unknown
- 2012-02-08 CR CR20120062A patent/CR20120062A/es unknown
-
2014
- 2014-08-06 US US14/452,884 patent/US20150011485A1/en not_active Abandoned
-
2015
- 2015-08-03 JP JP2015153237A patent/JP2016006093A/ja active Pending
- 2015-12-10 US US14/964,670 patent/US20160089360A1/en not_active Abandoned
-
2017
- 2017-01-05 JP JP2017000334A patent/JP2017081975A/ja active Pending
- 2017-01-23 AU AU2017200445A patent/AU2017200445B2/en active Active
- 2017-01-24 US US15/413,480 patent/US11576894B2/en active Active
-
2019
- 2019-06-24 HR HRP20191148TT patent/HRP20191148T1/hr unknown
- 2019-07-26 CY CY20191100795T patent/CY1121853T1/el unknown
-
2020
- 2020-04-29 AR ARP200101201A patent/AR118805A2/es unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR118805A2 (es) | Terapia de combinación para el tratamiento de la diabetes | |
CU20100200A7 (es) | Una composición farmacéutica que comprende n-(3,4-difluoro-2-4-iodofenilamino)-6-metoxifenil)-l-(2,3-dihidroxipropil)ciclopropano-l-sulfonamida, útil para el tratamiento y prevención del cáncer y de enfermedades inflamatorias | |
CU20110217A7 (es) | Derivados amino-propiónicos sustituidos como inhibidores de neprilisina | |
EA201001013A1 (ru) | Бис(сульфониламино)производные для применения в терапии | |
MA33745B1 (fr) | Piperidines substituees qui accroissent l'activite de p53, et utilisation de ces composes | |
CY1119357T1 (el) | Φαρμακευτικες συνθεσεις που περιλαμβανουν συνδετες υποδοχεων σιγμα | |
PT2323972E (pt) | Compostos de tetraciclina substituídos com c7-flúor | |
CO6470846A2 (es) | Derivados aminobut´ricos sustituidos como inhibidores de neprilisina | |
AR075583A1 (es) | Derivados de isoxazol/o-piridina con eslabon etilo o etenilo | |
MA37405A1 (fr) | Composés hétérocyclyle | |
NZ600210A (en) | Substituted 4-aminocyclohexane derivatives | |
TR201802944T4 (tr) | İlaç olarak azai̇ndazol veya di̇azai̇ndazol türünün türevleri̇ | |
AR061567A1 (es) | Compuestos puros enantiomericamente para el tratamiento de desordenes proliferativos | |
ECSP13012812A (es) | Formulaciones inmunosupresoras | |
SE0400284D0 (sv) | Novel compounds | |
EA201290632A1 (ru) | Производные бетулина | |
EA201692542A1 (ru) | Индановые и индолиновые производные и их применение в качестве активаторов растворимой гуанилатциклазы | |
EA201291217A1 (ru) | ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, СОДЕРЖАЩИЕ ПРОИЗВОДНЫЕ 1-(β-D-ГЛЮКОПИРАНОЗИЛ)-2-ТИЕНИЛМЕТИЛБЕНЗОЛА КАК ИНГИБИТОРЫ НЗПГ | |
DOP2011000113A (es) | Pirazolilaminopiridinas como inhibidores de fak | |
MX2021015056A (es) | Compuesto de pirrolopirimidina y uso del mismo. | |
CO6361855A2 (es) | Derivados de 7-hidroxi-benzoimidazol-4-il-,etanona e inhibidores de cinasa que enlaza pdz que contienen los mismos | |
MX364400B (es) | Compuestos de tetraciclina. | |
CO2020012353A2 (es) | Compuestos de pirazol sustituidos con heteroarilo y uso farmacéutico de los mismos | |
UY30847A1 (es) | Uso de derivados de mononitrato de dianhidrohexita como agentes para el tratamiento de trastornos intestinales | |
UY31824A (es) | Nuevos compuestos |